Approval · Notice of Compliance 11976 · 2011
TEVETEN: Notice of Compliance 11976
Issued January 4, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11976
- Date
- January 4, 2011
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Angiotensin II receptor (AT1) antagonist
Products in this notice
Medicinal ingredients
- EPROSARTAN MESYLATE 400 MG per TAB
- EPROSARTAN MESYLATE 600 MG per TAB